Beta Thalassemia/Sickle Cell Disease

Beta Thalassemia and Sickle Cell Disease (SCD) are inherited hemoglobin disorders with significant global health burdens. Beta thalassemia results from mutations in the β-globin gene, leading to reduced or absent beta-globin production and causing anemia of varying severity. 

The most severe form, β-thalassemia major, requires lifelong blood transfusions and iron chelation therapy to manage complications like iron overload. It is highly prevalent in Mediterranean, Middle Eastern, and South Asian populations, with carrier rates reaching up to 20% in some regions. 

SCD, caused by a point mutation in the β-globin gene (Glu→Val), leads to the production of abnormal hemoglobin S (HbS), which polymerizes under low oxygen conditions, distorting red blood cells into a sickle shape. This results in chronic hemolysis, vaso-occlusive crises, and multi-organ damage. SCD predominantly affects individuals of African, Middle Eastern, and Indian descent, with approximately 300,000 infants born with the disease annually worldwide. 

Both conditions can be diagnosed through newborn screening, and management includes supportive care, hydroxyurea (for SCD), blood transfusions, and, in select cases, curative therapies like hematopoietic stem cell transplantation.